Why emodepside formulation matters in resistant hookworm care

A newly published AJVR study adds important pharmacology detail to one of small-animal parasitology’s tougher clinical problems: what to do when routine dewormers fail against multi-anthelmintic drug-resistant canine hookworms. Investigators found that emodepside formulations are not interchangeable in dogs. In seven healthy client-owned dogs, oral dosing of the FDA-approved feline topical emodepside/praziquantel solution led to markedly greater absorption than the European canine modified-release tablet, and the two products did not meet bioequivalence criteria. Meanwhile, topical administration of the feline product produced far lower plasma concentrations than oral dosing. (pubmed.ncbi.nlm.nih.gov)

That matters because emodepside has increasingly been discussed in the U.S. as a salvage or last-line option for resistant Ancylostoma caninum infections, even though no emodepside product is approved for dogs in the United States. The July 11, 2025, Veterinary Vertex episode from AVMA Journals highlighted this exact issue, reflecting growing clinical interest as resistant hookworm cases spread beyond racing greyhounds into the broader pet dog population. An AAVP position paper published in 2025 said genetic and clinical evidence now suggests multi-anthelmintic drug-resistant hookworms are widely present in U.S. pet dogs, raising the stakes for treatment decisions. (veterinaryvertex.buzzsprout.com)

The new study, published online in 2025 and listed in AJVR for April 4, 2025, evaluated three dosing conditions: feline topical solution at 1 mg/kg given orally, canine modified-release tablet at 1 mg/kg given orally, and feline topical solution at 3 mg/kg given topically. Plasma pharmacokinetic profiles were followed for 21 days. The key finding was straightforward: the oral feline topical formulation was not bioequivalent to the oral canine tablet, and topical administration in dogs yielded emodepside concentrations 36- to 122-fold lower than oral administration. The authors said the higher oral absorption of the feline topical product raises potential safety concerns for extra-label use in dogs, while poor absorption after topical dosing suggests that route may be ineffective for resistant hookworm treatment. (pubmed.ncbi.nlm.nih.gov)

The study also helps explain some uncertainty seen in earlier resistant hookworm literature. A prior report on foxhounds with multiple anthelmintic drug resistance noted that clinicians used the cat topical formulation orally because the dog oral formulation was not commercially available in the U.S., and explicitly acknowledged that absorption and distribution “might not have been optimal.” More recent clinical guidance has likewise stressed that the cat topical emodepside product has no efficacy in dogs when administered topically and must be given orally if used extra-label, though those recommendations were based on limited evidence before this pharmacokinetic comparison was published. (vtechworks.lib.vt.edu)

Outside this study, expert commentary has been consistently cautious. AAHA’s Trends reported that oral extra-label emodepside can be the only effective option in some resistant cases, but warned that dogs should be screened for heartworm disease and, when appropriate, MDR1 status, and that pet parents should be counseled about risks and the extra-label nature of treatment. The 2025 AAVP position paper added another concern: emodepside is filaricidal, and its safety in heartworm-positive dogs has not been established. Those warnings become more important when a study shows that one formulation can produce substantially different systemic exposure from another. (aaha.org)

Why it matters: For veterinarians, the takeaway isn’t just that emodepside may help in resistant hookworm cases. It’s that formulation-specific pharmacokinetics can directly affect both safety and efficacy. A clinician might reasonably assume that matching the mg/kg dose across products would produce comparable exposure, but this study argues otherwise. In practical terms, that affects informed consent, monitoring, route selection, and how confidently clinicians can extrapolate from European canine data to extra-label U.S. use of a feline topical product. It also reinforces the broader antimicrobial stewardship-style principle now emerging in parasitology: confirm resistance where possible, document treatment failure, and avoid escalating to last-line therapies casually. (pubmed.ncbi.nlm.nih.gov)

There’s also a regulatory backdrop. In Europe, emodepside is available in veterinary products including Profender, an emodepside/praziquantel topical medicine authorized for cats, while the canine modified-release tablet referenced in the study has European regulatory footing but no U.S. equivalent. That leaves U.S. clinicians in a difficult position when confronting resistant hookworms: there is clinical demand for emodepside, but limited approved formulation choices and a narrow evidence base for extra-label use. (ema.europa.eu)

What to watch: The next step will likely be more work linking pharmacokinetic differences to clinical outcomes in naturally infected dogs, along with continued pressure for clearer protocols, resistance testing, and possibly a canine-labeled emodepside pathway in the U.S. market. (pubmed.ncbi.nlm.nih.gov)